Skip to main content

Table 1 Correlation between the factors and clinicopathological characteristics in the Chinese population (n = 70)

From: Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma

Clinical features

Case

RAD52 positive rate (%; mean ± SD)

P-value

Sample

 HCC

70

65.600 ± 25.079

P < 0.05*

 Adjacent tissue

70

48.057 ± 26.928

 

Age (years)

 ≤ 45

28

57.036 ± 28.299

P < 0.05*

 > 45

42

71.310 ± 21.157

 

Gender

 Male

61

66.918 ± 24.841

P > 0.05

 Female

9

56.667 ± 26.339

 

Smoking

 Yes

35

63.486 ± 26.579

P > 0.05

 No

35

67.714 ± 23.681

 

Drinking

 Yes

38

65.316 ± 26.366

P > 0.05

 No

32

65.938 ± 23.876

 

HBsAg infection

 Yes

50

68.700 ± 25.948

P > 0.05

 No

20

57.850 ± 21.431

 

AFP (ng/ml)

 ≤ 20

20

66.100 ± 21.885

P > 0.05

 > 20

50

65.400 ± 26.454

 

Tumor size (cm)

 ≤ 5

12

53.750 ± 23.848

P > 0.05

 > 5

6

45.000 ± 32.711

 

 Unknown

52

70.712 ± 22.667

 

Clinical stage

 I + II

32

63.656 ± 25.299

P > 0.05

 III + IV

38

67.237 ± 25.113

 

ALT

 ≤ 40

38

64.083 ± 27.055

P > 0.05

 > 40

32

70.517 ± 22.494

 

AST

 ≤ 40

28

65.280 ± 25.370

P > 0.05

 > 40

42

68.000 ± 25.263

 
  1. RAD52 radiation sensitive 52, HCC hepatocellular carcinoma, AFP alpha fetoprotein, HBsAg hepatitis B surface antigen, ALT glutamic-pyruvic transaminase, AST aspartate transaminase, SD standard deviation
  2. * P < 0.05